Clinical trial · Interventional
A Phase II Trial of Doxorubicin and Genexol-PM in Patients With Advanced Breast Cancer
NCT01784120CI-TRIAL-00020864unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate efficacy and toxicity of doxorubicin/Genexol-PM in metastatic breast cancer 1. Primary Purpose: response rate 2. Secondary purpose: toxicity, progression-free survival, overall survival
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Doxorubicin/Genexol-PM | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- doxotubicin/Genexol-PM
- interventionNames
- Drug: Doxorubicin/Genexol-PM
Primary outcomes (1)
- measure
- response rate
- timeFrame
- one year
Secondary outcomes (1)
- measure
- number of participants with adverse events
- timeFrame
- one year
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years of age or older adult women * Instrumentation measurable lesions with histologically confirmed advanced (recurrent or metastatic) breast cancer * ECOG 0-2 * Advanced breast cancer in the past, patients who did not receive chemotherapy * Recurrence if adjuvant chemotherapy and adjuvant chemotherapy in the past for more than 6 months until the patient * life expectancy more than 3 months * Agree in writing before the party to participate in a clinical trial to patients Exclusion Criteria: * immunohistochemical staining 3 + or FISH positive anti-HER 2 therapy patients * Severe infections requiring antibiotic therapy * Clinically significant heart disease * Pregnant or lactating woman * Uncontrolled symptoms in the central nervous system (CNS) metastases * Patients diagnosed with malignant tumors of other organs
References
Publications (0)
Data not yet available
No reference posted for this study.